ADAR2 editing activity in newly diagnosed versus relapsed pediatric high-grade astrocytomas

BMC Cancer

Table 1 Clinical features of four children with high-grade astrocytoma

	Case 1	Case 2	Case 3	Case 4
Sex	F	M	M	F
Age at diagnosis	≤ 13 years	≤ 12 years	≤ 8 years	≤ 3 years
Newly diagnosed tumor
Tumor location	P left	F left	FTP right	FP left
Resection	GTR	GTR	GTR	GTR
Histology	GBM	GBM	AA	GBM
Ki-67 (IHC)	>10%	50%	7-10%	60%
Pre-radiation CT	/	/	/	infant protocol (*)
RT doses	54 Gys plus TMZ	54 Gys plus TMZ	54 Gys plus TMZ	59 Gys (at time of 3 year old)
Post-radiation CT	TMZ (6 courses)	TMZ (6 courses)	TMZ (6 courses)	/
Recurrent tumor
DFS (months)	8	14	33	22
Recurrence	local	local	local	local
Resection	GTR	GTR	GTR	GTR
Histology	GBM	GBM	AA	GBM
Ki-67 (IHC)	40%	50%	60%	50%
Adjuvant CT	TMZ /PCV (1 course)°	TMZ /PCV (4 courses)°	TMZ /PCV (6 courses)°	TMZ /irinotecan (12 courses)
Outcome	dead	dead	dead	alive
LPS score	/	/	/	90
Disease	/	/	/	CR; off therapy
OS (months)	10	26	40	57

P Parietal, F Frontal, FTP Fronto-temporo-parietal, FP Fronto-parietal, GTR Gross Total Resection, GBM Glioblastoma, AA Anaplastic Astrocytoma, IHC immunohistochemistry, RT Radiotherapy, CT Chemotherapy, TMZ Temozolomide, DFS Disease Free Survival, PCV Procarbazine-Lomustine-Vincristine, LPS score Lansky performance score (from 100 to 0, with 100= healthy status), CR Complete Remission, OS Overall Survival.
°Until progression and death.
*Infant protocol according to the National Therapeutic Indications for infant with GBM: Methotrexate and Vincristine (1 course), Etoposide (1 course), cyclophosphamide and Vincristine (1 course), thiotepa (2 courses) followed by stem cell auto-grafting.

ISSN: 1471-2407